Cardiovascular Systems (Cardiovascular Systems) Accounts Receivable : $40.2 Mil (As of Dec. 2022)

View and export this data going back to 2006. Start your Free Trial

What is Cardiovascular Systems Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Cardiovascular Systems's accounts receivables for the quarter that ended in Dec. 2022 was $40.2 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Cardiovascular Systems's Days Sales Outstanding for the quarter that ended in Dec. 2022 was 59.74.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Cardiovascular Systems's Net-Net Working Capital per share for the quarter that ended in Dec. 2022 was $2.64.

Cardiovascular Systems Accounts Receivable Historical Data

The historical data trend for Cardiovascular Systems's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiovascular Systems Accounts Receivable Chart

Cardiovascular Systems Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Accounts Receivable

Get a 7-Day Free Trial

31.23

36.02

25.21

40.03

39.68

Cardiovascular Systems Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Accounts Receivable	Get a 7-Day Free Trial															34.94	34.67	39.68	40.26	40.23

Cardiovascular Systems Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Cardiovascular Systems Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Cardiovascular Systems's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	40.232	/	61.453	*	91
=	59.74

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Cardiovascular Systems's accounts receivable are only considered to be worth 75% of book value:

Cardiovascular Systems's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2022 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(132.002	+	0.75 * 40.232	+	0.5 * 41.191	-	72.117
-	0	-	0)	/	41.966
=	2.64

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Cardiovascular Systems Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Cardiovascular Systems's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiovascular Systems (Cardiovascular Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cardiovascular Systems Inc (NAS:CSII) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1225 Old Highway 8 Northwest, Saint Paul, MN, USA, 55112-6416

Website

https://www.csi360.com

Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.

Executives

Jeffrey S. Points	officer: Chief Financial Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Scott R Ward	director	RAYMOND HOLDINGS, LLC, 6410 BALLANTINE CT., INVER GROVE HEIGHTS MN 55077
Erik Paulsen	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Rhonda J. Robb	officer: Chief Operating Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Martha Goldberg Aronson	director	40 WEST HIGHLAND PARK DRIVE NE, HUTCHINSON MN 55350
Sachin H. Jain	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Alexander Rosenstein	officer: General Counsel & Corp. Secy	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Sandra Sedo	officer: Chief Compliance Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Kelvin K. Womack	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen J. Rempe	officer: Chief Human Resources Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
John M. Hastings	officer: VP Manufacturing & Operations	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen Stenbeck	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Ryan Egeland	officer: VP of Medical Affairs	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
David Whitescarver	officer: VP of Corp. Dev. & IP	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Laura Gillund	officer: Chief Talent Officer